🎉 M&A multiples are live!
Check it out!

Heidelberg Pharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Heidelberg Pharma and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Heidelberg Pharma Overview

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.


Founded

1997

HQ

Germany
Employees

105

Financials

LTM Revenue $11.7M

LTM EBITDA -$24.9M

EV

$90.0M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Heidelberg Pharma Financials

Heidelberg Pharma has a last 12-month revenue of $11.7M and a last 12-month EBITDA of -$24.9M.

In the most recent fiscal year, Heidelberg Pharma achieved revenue of $10.6M and an EBITDA of -$20.1M.

Heidelberg Pharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Heidelberg Pharma valuation multiples based on analyst estimates

Heidelberg Pharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $19.9M $10.6M XXX XXX XXX
Gross Profit -$3.2M $14.9M XXX XXX XXX
Gross Margin -16% 140% XXX XXX XXX
EBITDA -$17.4M -$20.1M XXX XXX XXX
EBITDA Margin -87% -190% XXX XXX XXX
Net Profit -$28.1M -$21.2M XXX XXX XXX
Net Margin -141% -200% XXX XXX XXX
Net Debt $4.6M n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Heidelberg Pharma Stock Performance

As of April 15, 2025, Heidelberg Pharma's stock price is EUR 3 (or $3).

Heidelberg Pharma has current market cap of EUR 120M (or $129M), and EV of EUR 83.8M (or $90.0M).

See Heidelberg Pharma trading valuation data

Heidelberg Pharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$90.0M $129M XXX XXX XXX XXX $-0.53

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Heidelberg Pharma Valuation Multiples

As of April 15, 2025, Heidelberg Pharma has market cap of $129M and EV of $90.0M.

Heidelberg Pharma's trades at 7.7x LTM EV/Revenue multiple, and -3.6x LTM EBITDA.

Analysts estimate Heidelberg Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Heidelberg Pharma and 10K+ public comps

Heidelberg Pharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $90.0M XXX XXX XXX
EV/Revenue 8.6x XXX XXX XXX
EV/EBITDA -4.2x XXX XXX XXX
P/E -5.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Heidelberg Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Heidelberg Pharma Valuation Multiples

Heidelberg Pharma's NTM/LTM revenue growth is 2%

Heidelberg Pharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Heidelberg Pharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Heidelberg Pharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Heidelberg Pharma and other 10K+ public comps

Heidelberg Pharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -47% XXX XXX XXX XXX
EBITDA Margin -203% XXX XXX XXX XXX
EBITDA Growth 16% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -201% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 53% XXX XXX XXX XXX
R&D Expenses to Revenue 285% XXX XXX XXX XXX
Opex to Revenue 352% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Heidelberg Pharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Contract Research & Manufacturing comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Heidelberg Pharma M&A and Investment Activity

Heidelberg Pharma acquired  XXX companies to date.

Last acquisition by Heidelberg Pharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Heidelberg Pharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Heidelberg Pharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Heidelberg Pharma

When was Heidelberg Pharma founded? Heidelberg Pharma was founded in 1997.
Where is Heidelberg Pharma headquartered? Heidelberg Pharma is headquartered in Germany.
How many employees does Heidelberg Pharma have? As of today, Heidelberg Pharma has 105 employees.
Is Heidelberg Pharma publicy listed? Yes, Heidelberg Pharma is a public company listed on ETR.
What is the stock symbol of Heidelberg Pharma? Heidelberg Pharma trades under HPHA ticker.
When did Heidelberg Pharma go public? Heidelberg Pharma went public in 2006.
Who are competitors of Heidelberg Pharma? Similar companies to Heidelberg Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Heidelberg Pharma? Heidelberg Pharma's current market cap is $129M
What is the current revenue of Heidelberg Pharma? Heidelberg Pharma's last 12-month revenue is $11.7M.
What is the current EBITDA of Heidelberg Pharma? Heidelberg Pharma's last 12-month EBITDA is -$24.9M.
What is the current EV/Revenue multiple of Heidelberg Pharma? Current revenue multiple of Heidelberg Pharma is 7.7x.
What is the current EV/EBITDA multiple of Heidelberg Pharma? Current EBITDA multiple of Heidelberg Pharma is -3.6x.
What is the current revenue growth of Heidelberg Pharma? Heidelberg Pharma revenue growth between 2023 and 2024 was -47%.
Is Heidelberg Pharma profitable? Yes, Heidelberg Pharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.